Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis.

about

Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis.

Item

http://www.wikidata.org/entity/Q55484524

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Chemotherapy with or without p ...... atic review and meta-analysis.

@en

Chemotherapy with or without p ...... atic review and meta-analysis.

@nl

type

Item

label

Chemotherapy with or without p ...... atic review and meta-analysis.

@en

Chemotherapy with or without p ...... atic review and meta-analysis.

@nl

prefLabel

Chemotherapy with or without p ...... atic review and meta-analysis.

@en

Chemotherapy with or without p ...... atic review and meta-analysis.

@nl

P1476

Chemotherapy with or without p ...... atic review and meta-analysis.

@en

P2093

Haitao Luo

http://www.w3.org/2001/XMLSchema#string

Haiyan Guo

http://www.w3.org/2001/XMLSchema#string

Jianxin Hu

http://www.w3.org/2001/XMLSchema#string

Weiguang Gu

http://www.w3.org/2001/XMLSchema#string

Yiyu Lu

http://www.w3.org/2001/XMLSchema#string

Zhihua Li

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Cancer statistics, 2010

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

P304

3697-3703

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S160147

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29983578

http://www.w3.org/2001/XMLSchema#string

P932

6027845

http://www.w3.org/2001/XMLSchema#string